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Abstract
The Drosophila Dysfusion basic-helix-loop-helix-PAS (bHLH-PAS) protein controls the
transcription of genes that mediate tracheal fusion. Dysfusion is highly related to the mammalian
Nxf protein that has been implicated in nervous system gene regulation. Toward the goal of
understanding how Dysfusion controls fusion cell gene expression, the biochemical properties of
Dysfusion were investigated using protein interaction experiments, cell culture-based transcription
assays, and in vivo transgenic analyses. Dysfusion dimerizes with the Tango bHLH-PAS protein,
and together they act as a DNA binding transcriptional activator. Dysfusion/Tango binds multiple
NCGTG binding sites, with the following preference: TCGTG > GCGTG > ACGTG > CCGTG.
This binding site promiscuity differs from the restricted binding site preferences of other bHLH-
PAS/Tango heterodimers. However, it is identical to the binding site preferences of mammalian Nxf/
Arnt, indicating that the specificity is evolutionarily conserved. Germ line transformation
experiments using a fragment of the CG13196 Dysfusion target gene allowed identification of a
fusion cell enhancer. Experiments in which NCGTG sites were mutated individually and in
combination revealed that TCGTG sites were required for fusion cell expression but that the single
ACGTG and GCGTG sites present were not. Finally, a reporter transgene containing four tandemly
arranged TCGTG elements has strong expression in tracheal fusion cells. Transgenic misexpression
of dysfusion further revealed that Dysfusion has the ability to activate transcription in multiple cell
types, although it does this most effectively in tracheal cells and can only function at
midembryogenesis and later.
Members within a related group of transcription factors often control expression of different
gene sets despite their protein sequence conservation. This differential gene regulation can
arise from a variety of mechanisms. These mechanisms include 1) different transcription factor
DNA binding specificities, 2) interactions with different co-regulatory proteins, and 3)
expression in different cell types that may vary in their chromatin states. The basic-helix-loop-
helix-PAS (bHLH-PAS)2 proteins comprise a group of highly conserved transcription factors
that control a variety of developmental and physiological events (1). The defining structural
feature of this class of bHLH proteins is the presence of the PAS domain, a multifunctional
interaction domain. In Drosophila there are 11 bHLH-PAS family members, and they control
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disparate processes, including neurogenesis, tracheal formation, tracheal fusion, dendrite
morphology, retinal cell fate, circadian rhythms, hormone responsiveness, appendage identity,
and the response to hypoxia. Most of these proteins have mammalian and nematode orthologs.
One of the issues regarding bHLH-PAS protein function is how these related proteins regulate
the different sets of genes that execute these biological phenomena.
One mechanism of differential bHLH-PAS protein gene control involves protein binding to
different co-regulatory proteins. The Drosophila Single-minded (Sim) and Trachealess (Trh)
bHLH-PAS proteins both dimerize with the Tango (Tgo) bHLH-PAS protein, and bind the
same ACGTG sequence (2,3). However, Trh directly interacts with the Ventral veinless (Vvl)
POU-homeobox protein and activates expression of tracheal target genes that contain both Trh
and Vvl binding sites (4). In contrast, Sim is unable to directly bind Vvl and, thus, unable to
activate tracheal gene expression. In other cases, transcriptional specificity arises from
differences in the basic region protein sequences that results in recognition of different DNA
sequences. For example, the Drosophila Spineless (Ss) protein also pairs with Tgo but
preferentially binds a GCGTG sequence unlike the Sim/Tgo and Trh/Tgo heterodimers that
prefer ACGTG (5). Thus, similar to other transcription factor families, bHLH-PAS proteins
use multiple methods to differentially regulate gene transcription in vivo.
The last Drosophila bHLH-PAS protein to be discovered was the dysfusion (dys) gene (6).
This gene has a mammalian ortholog (Nxf) (7) and a nematode ortholog (C15C8.2) (8). The
Dys DNA binding basic region sequence is highly conserved but not identical among the
different animal species (Table 1). It is markedly divergent compared with the basic regions
of other bHLH-PAS proteins. DNA binding and transient transfection studies on human Nxf
revealed that Nxf dimerized with the aromatic hydrocarbon nuclear translocator (Arnt) protein,
the mammalian Tgo ortholog, and bound ACGTG, GCGTG, and TCGTG sequences (7,9,
10). Which of these sequences is utilized in vivo to control gene expression by Nxf is unknown.
The Drosophila dys gene is prominently expressed in tracheal fusion cells. These cells reside
at the tip of the growing tracheal tubules and mediate the fusion of adjacent tracheal branches.
Elimination of dys function by mutation and RNA interference resulted in an absence of
tracheal fusion (6), and four genes were identified whose fusion cell transcription was abolished
or reduced in dys mutants (11) and are potential candidates to be directly regulated by Dys.
The identification of these target genes allows biochemical and molecular experiments that
can test the mechanistic role of dys in controlling fusion cell transcription.
In this paper we used in vitro and in vivo approaches to study how Dys regulates gene expression
in tracheal fusion cells. We showed that Dys dimerizes with Tgo, resulting in nuclear
translocation of the Dys/Tgo complex. The Dys/Tgo dimer then acts to activate transcription.
The Dys basic region differs from mammalian Nxf at 3 amino acid sites. Yet transient
transfection experiments revealed that Dys/Tgo, like Nxf/Arnt, binds to multiple NCGTG
sequences with a specificity conserved between mammalian and Drosophila proteins. This is
in contrast to the results of identical experiments with Sim/Tgo and Trh/Tgo which
demonstrated that they are restricted to a single ACGTG binding site specificity. Drosophila
transgenic approaches were employed to test how Dys/Tgo controls transcription in vivo.
Reporter gene transformants containing a 1.0-kb fragment of the fusion cell-expressed
CG13196 Dys target gene drives fusion cell expression. Mutation of ACGTG, GCGTG, and
TCGTG sites in the CG13196 fragment along with analysis of a transgene containing TCGTG
multimers revealed that TCGTG is required for expression in vivo. This indicated that Dys/
Tgo uses a novel bHLH-PAS protein DNA binding specificity in vivo to control fusion cell
gene expression. Further dys misexpression experiments revealed that Dys/Tgo has the ability
to ectopically activate CG13196 transcription in multiple cell types but is temporally blocked
from acting until mid-embryogenesis.
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S2 Cell Transient Expression Plasmids and Assays
The dys expression plasmid, pAct-dys, was generated by cloning an EcoRV fragment of a full-
length dys cDNA (6) into the EcoRV site of the pAct5CSRS (12). This pAct-dys plasmid
contains the entire dys coding sequence behind an actin5C (Act) promoter. The pAct-dys-Δb
plasmid has a deletion of the entire Dys basic region (NKSTKGASKMRR), which is expected
to abolish DNA binding. It served as a negative control. The dys-Δb fragment was cloned into
the SacI site of pAct5CSRS. The construction of pAct-sim, pAct-tgo, and pAct-trh were
previously described (2). The reporter plasmids contained four tandemly linked copies of an
identical 24 bp Toll CME-4 sequence (13) with a different, potential Dys/Tgo NCGTG binding
site (underlined): CTAGAAATTTGTACGTGCCACAGA,
CTAGAAATTTGTCCGTGCCACAGA, CTAGAAATTTGTGCGTGCCACAGA, and
CTAGAAATTTGTTCGTGCCACAGA. Each fragment was cloned into pCR-Blunt II-TOPO
(Invitrogen), cut with KpnI and SacI, and then cloned into the KpnI and SacI sites of the
pGL-3 enhancer tester vector (Promega). pGL3 utilizes a firefly luciferase (luc) reporter gene.
The full-length Nxf cDNA coding sequence was generated by PCR from pEGFP-LE-PAS (9)
using the primers 5′-GGTACCATGTACCGATCCACCAAGGGCG-3′ and 5′-
GGTACCTCAAAACGTTGGTTCCCCTCCA-3′. The PCR product was cloned into pGEM-
T Easy vector (Promega), digested with KpnI, and cloned into the KpnI site of pAct5CSRS,
generating pAct-Nxf. The full-length human Arnt coding sequence was contained on a BamHI
fragment derived from pBM5/Neo/M1-1 (14). This fragment was cloned into the BamHI site
of pAct5CSRS, generating pAct-Arnt. The pAc5.1/V5-His/lacZ transfection control plasmid
(Invitrogen) consists of the actin5C promoter driving β-galactosidase (lacZ) gene expression.
The LE-PAS and Arnt clones were generously provided by Cam Patterson.
Transient transfection in Drosophila S2 cells was carried out using an Effectene transfection
reagent protocol (Qiagen). Each transfection was performed 6 times using 1 µg of total DNA.
The total DNA included 0.3 µg for each reporter and expression plasmid, 0.1 µg of pAc5.1/
V5-His/lacZ internal control plasmid, and additional pAct5CSRS DNA to achieve a final DNA
concentration of 1 µg. After 48 h of growth, luc expression was assayed using a luc assay kit
(Promega) and a Typhoon 9400 variable mode imager (Amersham Biosciences). β-
Galactosidase activity was measured with a β-galactosidase assay kit (Promega) and enzyme-
linked immunosorbent assay and was used to normalize transfection efficiency.
Protein-Protein Interaction (HA Pulldown) Assays
The dys cDNA coding sequence was cloned into pAHW (T. Murphy, Carnegie Institution) in
which an N-terminal hemagglutinin (HA) tag was added to dys. The dys cDNA was PCR-
amplified using primers 5′-CACCATGCCAAATGCTATTGGAGCTAG-3′ and 5′-
CACACTTAATACTAACCTCTATCCTC-3′. The PCR product was cloned into pENTR
using the pENTR TOPO cloning kit (Invitrogen). Then the dys cDNA was recombined into
pAHW using the Gateway LR Clonase enzyme mix (Invitrogen).
S2 cells were transiently transfected with 0.5 µg of pAct-tgo and 0.5 µg pAct-HA-dys
individually or in combination using Effectene. pAct5CSRS DNA was added to achieve a final
DNA concentration of 1 µg when necessary. After 48 h of growth, whole-cell extracts were
prepared by sonication of cells in lysis buffer (20 mM Tris-HCl, pH 7.5, 0.5% Nonidet P-40,
150 mM NaCl, 3mM EDTA, 3mM EGTA, 10 µg/ml aprotinin, 10 µg/ml of leupeptin, 10 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride). Extracts were incubated with 30 µl of anti-
HA-conjugated-agarose beads (Sigma) overnight at 4 °C. The extracts and HA-associated
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proteins were electrophoresed on 10% SDS-polyacrylamide gels followed by Western blot
analysis using mAb-Tgo antibody (2).
CG13196 Transgenic Strains
The sequence from −985 to −1 in the 5′-flanking sequence of CG13196 was PCR-amplified
using the primer pair GGTACCCTATAAGTATGGCAAGAGGTGGC (KpnI site is
underlined) and AGATCTGATTGGGCCGCAAGTGATA (BglII site is underlined). This 1.0-
kb fragment was cloned into the KpnI and BglII sites of pH-Stinger (15), which is a nuclear
green fluorescent protein (GFP) P-element reporter. The CG13196 1.0-kb fragment has 3
TCGTG, 1 ACGTG, and 1 GCGTG potential Dys-Tgo binding sites. These sites were mutated
individually and in combination using a QuikChange II XL site-directed mutagenesis kit
(Stratagene). Each ACGTG, GCGTG, and TCGTG site was mutated to GATCC. Five
CG13196 1.0-kb plasmids were generated: unmutated, all 5 (A/G/T)CGTG sites mutated, all
TCGTG sites mutated, single ACGTG site mutated, and single GCGTG site mutated. Each
transgene was introduced into the Drosophila germ line using standard P-element
transformation techniques. Three independent lines of each transgene were analyzed for
embryonic expression.
Multimerized TCGTG Transgenic Strain
The 4× 24-bp Toll CME-4 sequence that contains TCGTG, described above under “S2 Cell
Transient Expression Plasmids and Assays” was used to generate a 4X-TCGTG-GFP
transgenic reporter train. The 4X-TCGTG fragment was excised from the pCR-Blunt II-TOPO
plasmid by cutting with KpnI and BglII and then cloned into the KpnI and BglII sites of pH-
Stinger to yield P[4XTCGTG-GFP]. After introduction into the Drosophila genome, two
independent lines were analyzed for embryonic and larval reporter gene expression.
Transgenic Misexpression Strains
The UAS-dys and UAS-dys-Δb transgenic lines were previously described (11). The dys mutant
embryos analyzed were a trans-heterozygous combination of the dys2 and dys3 null mutants
(11). Gal4 drivers included breathless (btl)-Gal4 (most tracheal cells), engrailed (en)-Gal4
(ectodermal stripes), scabrous (sca)-Gal4 (nervous system), and twist (twi)-Gal4 (mesoderm)
(6,16,17).
Embryonic Immunostaining and in Situ Hybridization
Whole-mount embryos were immunostained and subjected to in situ hybridization using
standard techniques (18). The following primary antibodies were used for immunostaining: rat
anti-Dys (1:200), anti-Tgo monoclonal antibody (1:1), and rabbit anti-GFP (1:1000; AbCam).
The following secondary antibodies were used: Alexafluor 488-labeled anti-rabbit IgG (1:200;
Invitrogen), Alexafluor 488-labeled anti-mouse IgG (1:200; Invitrogen), and Cy3-labeled anti-
rat IgG (1:200; PerkinElmer Life Sciences). The CG13196 cDNA plasmid, RE44287 (Open
Biosystems), was used to generate an RNA probe for in situ hybridization. Embryos were
examined using a Zeiss Pascal confocal microscope.
RESULTS
Dys Forms a Heterodimer with Tgo in Vivo
Tgo forms heterodimers in vivo with multiple bHLH-PAS proteins, including Sim, Similar
(Sima), Ss, and Trh (2,5). In the absence of a bHLH-PAS partner protein, Tgo resides at low
levels in the cytoplasm. In the presence of a partner protein, the Tgo-containing heterodimer
translocates and accumulates in the nucleus (16). Thus, nuclear appearance of Tgo generally
indicates the occurrence of a partner bHLH-PAS protein (note, there may be exceptions to this
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rule; Refs. 19 and 20). It also seemed likely that Dys functions as a DNA binding heterodimer
with Tgo. First, nuclear Tgo is present at sites of dys expression (6). This is particularly evident
in the embryonic leading edge cells, in which no other bHLH-PAS protein besides Dys is
known to be present. Second, the Nxf protein, which is the mammalian Dys ortholog, dimerizes
with Arnt and Arnt2, the mammalian Tgo orthologs (7,10). To determine whether
Drosophila Dys/Tgo heterodimerization occurs, biochemical protein binding assays, in vivo
genetic and misexpression experiments, and cell culture-based molecular assays were
performed.
Both tgo and HA-tagged dys were cotransfected into Drosophila S2 tissue culture cells, and
HA-tagged Dys protein complexes were purified with anti-HA-agarose beads. Western blot
analysis of the protein complex with anti-Tgo revealed that Tgo was bound to HA-Dys (Fig.
1A), indicating a direct, biochemical association between Dys and Tgo.
Immunostaining of wild-type embryos with anti-Dys and anti-Tgo showed strong nuclear
colocalization of both proteins in the leading edge cells (Fig. 2, A–C). Immunostaining of
dys mutant embryos using dys alleles predicted to generate truncated proteins terminating in
the HLH regions revealed the absence of nuclear Tgo in the leading edge cells (Fig. 2,D and
F), indicating that Tgo nuclear localization requires the presence of (and presumably direct
interaction with) Dys. The dys gene is also prominently expressed in tracheal fusion cells, and
both nuclear Dys and Tgo appear in fusion cells (Fig. 2, G–I). However, because Trh, another
partner of Tgo, is also expressed in tracheal cells, including fusion cells, the appearance of
nuclear Tgo cannot be unambiguously ascribed to the appearance of Dys. However, careful
examination of Tgo levels in wild-type tracheal nuclei indicated that it is at higher levels in
fusion cells than other tracheal cells (Fig. 2, G–I). In dys mutant embryos the levels of nuclear
Tgo in fusion cells are reduced to the same levels as the surrounding tracheal cells (Fig. 2, J–
L). This reduction occurs even though Trh levels are increased in fusion cells of dys mutants
(6, 11). These results indicated that some of the nuclear Tgo in fusion cells is due to
heterodimerization with Dys and subsequent nuclear import of the complex. It also indicated
that there is a pool of cytoplasmic Tgo that normally turns over rapidly but is stabilized upon
interaction with partner bHLH-PAS proteins. This pool can expand when increasing amounts
of Dys are present in fusion cells.
Misexpression of bHLH-PAS proteins was previously employed in assays to demonstrate that
these proteins dimerize with Tgo in vivo (5,16). The UAS-dys transgene was ectopically
expressed in ectodermal stripes with en-Gal4. Immunostaining with anti-Dys and anti-Tgo
revealed that both proteins were localized to nuclei in en stripes (Fig. 2, M–O). This reinforces
the notion that the appearance of Dys protein results in dimerization with Tgo and subsequent
translocation into nuclei. Similar results were obtained with misexpression of UAS-Δb-dys (Fig.
2, P–R), indicating that DNA binding of Dys/Tgo is not required for stable localization in
nuclei. This result is similar to that observed for Sim/Tgo (21). In summary, the biochemical
experiments showed that Dys and Tgo dimerize. The genetic and misexpression results
confirmed that this association also occurs in the embryo and further indicated that Dys/Tgo
translocates into nuclei, where the dimer likely acts to bind DNA.
Dys/Tgo Activates Transcription and Binds Multiple NCGTGBinding Sites
Generally, bHLH-PAS dimers containing Tgo/Arnt bind an asymmetric E-box with the
sequence NCGTG (1). The basic regions primarily contribute to DNA binding, although
additional sites on the protein may contribute. Transient transfection assays using
Drosophila cell culture have been successful in determining the binding site specificity of
Drosophila bHLH-PAS proteins (2). Consequently, this approach was employed to study the
specificity of Dys/Tgo. Tgo binds the half-site GTG (2,3). Dys has an Arg residue at basic
region position 12 (Table 1), and according to the “B-1” rule for bHLH proteins (13,22), it will
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bind an NC half-site. Consequently, Dys/Tgo should bind an NCGTG sequence. This is
consistent with known Nxf/Arnt/Arnt2 binding sites of ACGTG, CGGTG, GCGTG, and
TCGTG (7,9,10). The Drosophila Dys basic region (NKSTKGASKMRR) has three amino
acid substitutions compared with human Nxf (YRSTKGASKARR; differences are
underlined), which could cause changes inDNAbinding specificities between the two proteins.
Thus, we tested Dys/Tgo in an S2 cell transient transfection assay to test the binding specificity
of Dys/Tgo as well as to determine whether Dys/Tgo was a transcriptional activator.
Reporter genes were constructed that were identical except that each had four copies of either
ACGTG, CCGTG, GCGTG, or TCGTG. These constructs were cotransfected with plasmids
that expressed either tgo, dys, or dys-Δb in various combinations. The dys-Δb plasmid lacks
the Dys basic region and presumably is unable to bind DNA. The transfection experiments that
lacked either tgo or dys or combined tgo with dys-Δb acted as negative controls. The results
(Fig. 1B) showed that Dys/Tgo acts as a transcriptional activator. Strongest activation was with
TCGTG (17× control) followed by GCGTG (10×). In addition ACGTG showed significant
activation (7×), whereas CGGTG was significantly lower (3×). Consistent with the need for
both tgo and dys, all reporters showed low levels of activation when either Tgo or Dys was
absent or when Dys-Δb/Tgo heterodimers were analyzed, indicating that activation requires
both Dys and Tgo proteins and is due to direct DNA binding.
Binding Site Promiscuity is Unique to Dys/Tgo
Dys/Tgo binds all four NCGTG sequences, ACGTG, CGGTG, GCGTG, and TCGTG,
relatively well. Other studies have shown that Sim/Tgo preferentially binds ACGTG better
than GCGTG, and Ss/Tgo preferentially binds GCGTG better than ACGTG (21). However,
previous studies with Drosophila bHLH-PAS proteins did not systematically assay all four
NCGTG reporters as was done here with Dys/Tgo. Thus, it is possible that other Drosophila
bHLH-PAS heterodimers, besides Dys/Tgo, may also bind sequences other than their preferred
sequence. To test this we utilized the same reporters assayed with Dys/Tgo in assays containing
sim, tgo, and trh expression plasmids in the S2 cell transient transfection assay. The results
(Fig. 1, C and D) showed that Sim/Tgo and Trh/Tgo differed from Dys/Tgo in that they were
specific for ACGTG binding sites and did not significantly activate CGTGT, GCGTG, or
TCGTG sites. Thus, these assays indicated that Dys/Tgo has a broader specificity than Sim/
Tgo and Trh/Tgo, and Dys/Tgo also strongly binds TCGTG, a sequence unique to the Dys/
Tgo/Nxf/Arnt class of bHLH-PAS proteins.
Evolutionary Conservation of Dys/Nxf Biochemical Function
Because the promiscuity of Dys/Tgo binding specificity appears unique among bHLH-PAS
proteins, it is important to assess whether this feature is evolutionarily conserved. This seems
likely, since the results of our analysis of Dys/Tgo DNA binding was similar to the results
obtained by Ooe et al. (2004) on Nxf/Arnt using similar, but not identical, assays. In contrast,
a more limited analysis demonstrated strong binding to ACGTG but not GCGTG (9). To further
investigate the similarities in transcriptional specificity between Drosophila and mammalian
proteins and their ability to substitute for each other, we utilized the S2 cell system and the
four NCGTG reporters with human Nxf and human Arnt expression plasmids. The results
shown in Fig. 1E revealed that TCGTG, GCGTG, and ACGTG were activated strongly by
Nxf/Arnt, whereas CCGTG showed little activation. Essentially, the same results were
obtained when Tgo was substituted for Arnt (Fig. 1E), although Tgo was slightly less active
with Nxf compared with Arnt. Comparison of the results indicated that using identical assays,
Dys/Tgo and Nxf/Arnt show similar promiscuous DNA binding specificities. Their
specificities show a similar preference spectrum with TCGTG > GCGTG > ACGTG >
CCGTG. This result confirms the analysis by Ooe et al. (2004). In addition, Dys and Nxf are
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both able to function with Tgo, reinforcing the strong conservation between Drosophila and
mammalian proteins.
In Vivo Identification of a Tracheal Fusion Cell Enhancer
The S2 cell transient transfection results indicated that Dys can dimerize with Tgo and activate
transcription of multiple NCGTG reporter genes. However, definitive insight into the role of
Dys in controlling tracheal fusion cell transcription requires in vivo analysis. This is a two-step
process involving transgenic identification of a fragment of DNA that can drive fusion cell
transcription and then mutation and analysis of potential Dys binding sites. Genetic studies
have identified four genes (CG13196, CG15252, members only (mbo), and shg (shotgun))
whose expression is abolished or reduced in dys mutants (11). The CG13196 gene was chosen
for further study because (a) its embryonic expression is specific for fusion cells and, thus, its
cis-regulation may be relatively uncomplicated, (b) the gene is activated in fusion cells after
the appearance of Dys, consistent with direct control by Dys/Tgo, (c) its expression is
ectopically expanded in all tracheal cells upon misexpression of dys (11), (d) its gene structure
is relatively simple with small introns and a short 5′-flanking region, and (e) it has multiple
NCGTG putative Dys/Tgo binding sites in its 5′-flanking region.
CG13196 encodes a member of the zona pellucida family of membrane proteins (23).
Previously, we showed using an ectopic expression assay that CG13196 has the ability to
promote tracheal fusion, suggesting a role in cell adhesion (11). The Drosophila melanogaster
CG13196 gene contains four exons and lies within the large first intron of the Buffy gene. The
sequence interval 5′ of CG13196 exon 1 and exon 2 of Buffy is only 985 bp. This region has 3
TCGTG, 1 ACGTG, 1 GCGTG, and no CCGTG sites (Fig. 3A). This entire fragment was
cloned into pH-Stinger, which is a GFP-based enhancer tester vector (15), to yield the transgene
P[1.0-CG13196-GFP]. Analysis of embryos immunostained for both GFP expression with
anti-GFP and CG13196 RNA by in situ hybridization revealed that P[1.0-CG13196-GFP] is
expressed in all tracheal fusion cells, identically to CG13196 (Fig. 3, B–D). Thus, the
CG13196 1.0-kb upstream fragment contains a tracheal fusion cell enhancer.
Mutational Analysis Reveals That TCGTG Is an Important Dys/Tgo Binding Site In Vivo
Because the 1.0-CG13196 fragment has five NCGTG sites that could act as binding sites for
Dys/Tgo, these sites were mutagenized individually and in combination to the sequence
GATCC, which is not expected to bind Dys/Tgo. Four variants were generated: P[1.0-mut(all)-
CG13196-GFP], in which all 5 NCGTG sites were mutated, P[1.0-mut(3TCGTG)-CG13196-
GFP], in which all TCGTG sites were mutated, P[1.0-mut(ACGTG)-CG13196-GFP], in which
the single ACGTG was mutated, and P[1.0-mut-(GCGTG)-CG13196-GFP], in which the
single GCGTG site was mutated. Three independent lines bearing each transgenic construct
were analyzed for GFP expression. The results indicated that mutation of all five NCGTG sites
resulted in loss of fusion cell expression (Fig. 4, C and D). Mutation of just the three TCGTG
sites also resulted in loss of fusion cell expression (Fig. 4, E and F). In contrast, the mutation
of just the ACGTG or GCGTG sites had no affect on fusion cell expression (Fig. 4, G–J). These
results provided strong evidence that Dys/Tgo directly regulates CG13196 expression and acts
as a transcriptional activator in vivo. They also demonstrated that the TCGTG sequences are
required. The ACGTG and GCGTG sequences are not absolutely required for fusion cell
expression, although it remains possible that they contribute to fusion cell expression in
association with the TCGTG binding sites.
Tracheal Fusion Cell Expression of a Multimerized TCGTG containing Transgenic Reporter
Further evidence for the ability of Dys/Tgo to activate transcription in vivo via a TCGTG
sequence was sought by analyzing a transgenic reporter, P[4XTCGTG-GFP], containing four
TCGTG sequences fused to a minimal promoter. This experiment was based on the successful
Jiang and Crews Page 7













use of a 4× ACGTG transgenic reporter, which showed expression in CNS midline cells and
trachea (2,13) that are sites of sim and trh function, respectively. Embryonic expression of P
[4X-TCGTG-GFP] was observed in two cell types, tracheal fusion cells (Fig. 4, K–M) and the
salivary glands (data not shown). Recently, it was shown that the pH-Stinger vector used here
is expressed in the salivary gland by itself (24), and salivary gland GFP expression was also
observed in the CG13196 transgenes described above. Because dys is not expressed in the
salivary gland (6), we conclude that the only sites of embryonic expression of P[4X-TCGTG-
GFP] are in the fusion cells, sites of Dys/Tgo. P[4X-TCGTG-GFP] expression was absent in
dys mutant embryos (Fig. 4, N and O), demonstrating that expression was dependent on dys,
as expected. These results provide additional evidence that Dys/Tgo binds TCGTG in vivo.
The P[4X-TCGTG-GFP] strain showed expression in fusion cells of all four dys-positive
branch types: dorsal branch, dorsal trunk, lateral trunk, and ganglionic branch. However,
expression was not observed in other sites of dys expression, including brain, foregut atrium,
leading edge, and anal pad (data not shown). This was reminiscent of the 4X-ACGTG transgenic
strain, in which only a subset of sim and trh sites showed expression (2). Interestingly, the P
[4X-TCGTG-GFP] strain showed segmental restriction of fusion cell expression in all four
branch types. Expression was present in fusion cells of all posterior segments but was absent
in anterior segments (Fig. 4M). Both the dorsal branch and lateral trunk failed to show GFP
fusion cell expression in the four to five anterior-most tracheal segments despite the appearance
of Dys protein. The dorsal trunk and ganglionic branch lacked GFP fusion cell expression in
the anterior-most two to three tracheal segments. These differences in GFP expression in
various Dys-positive cell types suggest that additional complexities exist regarding how Dys
controls transcription in fusion cells.
dys Misexpression and Fusion Cell Transcription
In a previous paper UAS-dys was expressed throughout the entire trachea using btl-Gal4, and
CG13196 was shown to be ectopically expressed throughout the trachea (11). We wondered
whether dys could also drive CG13196 expression in additional cell types, since this would
provide insight into the nature of other factors required for fusion cell gene expression. In these
experiments, UAS-dys was misexpressed in (a) epidermal stripes using en-Gal4, (b)
mesodermal cells using twi-Gal4, and (c) peripheral and central nervous system precursors
using sca-Gal4. Misexpression embryos were stained with anti-Dys to gauge dys expression
and hybridized to a CG13196 probe. In all cells in which dys was misexpressed, Dys protein
was nuclear and appeared at high levels (Fig. 5B, E, H, K, N, and Q). This confirms results
seen with other bHLH-PAS proteins that dimerization with Tgo and subsequent nuclear
localization occurs in most, if not all, cell types throughout development (16).
The ability of dys to activate CG13196 expression showed spatial and temporal differences.
When misexpressed in the trachea using btl-Gal4, dys strongly activated CG13196 in most, if
not all, tracheal cells when assayed at stage 16 (Fig. 5, A–C) (11). However, when assayed at
stage 14, CG13196 expression was not yet induced in btl-Gal4 UAS-dys embryos even though
Dys protein was present at high levels (Fig. 5, D–F). This indicated an early developmental
block to Dys/Tgo activation. When expressed in en epidermal stripes, CG13196 expression
was observed in some cells but not others when assayed at stage 16 (Fig. 5, G–I). Expression
is absent from the ventral epidermis but present in the dorsal epidermis, indicating a regional
difference. However, in the dorsal epidermis expression was still patchy, with no clear pattern.
Thus, equivalent cells in different segments showed varying levels of CG13196 expression,
indicating that ectopic CG13196 expression in epidermal cells is sporadic and not restricted to
specific epidermal cell types. Relative levels of Dys appeared high in both cells that were
CG13196-positive and also CG13196-negative, indicating that high level dys expression is not
an obvious reason for CG13196 expression differences. Similar to activation of CG13196 by
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tracheal dys, CG13196 was not activated in en stripes when assayed at earlier stages (Fig. 5,
J–L). Similar results to en misexpression were observed in the mesoderm. Dys could induce
CG13196 in some mesodermal cells, but not all, when induced by twi-Gal4 (Fig. 5, M–O). The
misexpression of dys can induce developmental defects. For example, the twi-Gal4 UAS-dys
embryos fail to germ-band retract (Fig. 5, M–O). Ectopic expression of CG13196 in neural
precursors and their progeny by sca-Gal4 was relatively rare (Fig. 5, P and R). Thus, ectopic
expression of dys can activate CG13196 transcription ectopically, but the robustness of
activation is dependent on both temporally and spatially controlled factors.
DISCUSSION
The Drosophila Dys bHLH-PAS protein is an important regulator of tracheal fusion cell gene
expression. This paper mechanistically deals with how it regulates transcription. The results
demonstrate that Dys dimerizes with Tgo, and together they activate transcription of target
genes. The target specificity of Dys/Tgo was analyzed systematically in cell culture transient
transfection assays and showed promiscuity in binding site specificity by binding multiple
NCGTG sequences. The quantitative preference was TCGTG > GCGTG > ACGTG >
CGGTG. Using the same assay it was shown that this promiscuity is biochemically distinct
from the actions of the Sim/Tgo and Trh/Tgo bHLH-PAS proteins, which significantly bind
only ACGTG. This broad specificity of Dys/Tgo is identical to that for mammalian Nxf/Arnt,
suggesting that the broad specificity has functional significance. Expression of the CG13196
gene in tracheal fusion cells requires dys function, which suggested that it might be a direct
Dys/Tgo target gene. Using germ line transformation, we identified a 1.0-kb fragment of
CG13196 that drives expression of a reporter gene in fusion cells identically to the endogenous
gene. This fragment had ACGTG, GCGTG, and TCGTG sites, and these sites were mutated
and tested for their potential role in regulating fusion cell transcription. Mutation of the TCGTG
sites abolished transcription, whereas mutation of either ACGTG or GCGTG did not.
Additional evidence that Dys/Tgo binds TCGTG in vivo emerged from results showing that a
multimerized 4X-TCGTG transgene was expressed exclusively in tracheal fusion cells in a
dys-dependent manner. Consequently, we conclude that Dys/Tgo binds TCGTG sequences in
vivo to regulate CG13196 gene expression. All 12 sequenced Drosophila species have at least
2 TCGTG sequences in the homologous intergenic regions between CG13196 and Buffy exon
2. Interestingly, all 12 species have a GCGTG sequence adjacent to the TCGTG sequences,
whereas ACGTG sequences are often absent. Thus, although TCGTG has been shown to play
an in vivo role as a Dys/Tgo binding site and GCGTG is not required, the sequence conservation
suggests that GCGTG sequences could still play an accessory role in CG13196 regulation.
Binding Site Specificities of bHLH-PAS Proteins
To a partial extent, the ability of bHLH and bHLH-PAS proteins to regulate different target
genes depends on their DNA binding site specificities. Considerable insight into this issue has
been gained from mutational and structural analyses of bHLH proteins. However, no
mutational or structural data exists for Dys/Tgo or Nxf/Arnt, so correlating the unique DNA
binding specificity of Dys and Nxf to specific amino acid residues within the basic region is
only speculative at this point. In addition, it is possible that protein sequences outside the basic
regions, such as the HLH and PAS domains, may influence DNA binding specificity (25).
Nevertheless, there are several features of the Dys basic region worth noting.
Table 1 shows the basic regions of selected bHLH-PAS proteins whose DNA binding
specificities are known. The Arg-12 residue, which is the only residue conserved in all the
basic regions shown, dictates the C at position −1 of the binding site (−2NC|GTG3), which is
also a conserved element of all of the half-sites (22). The Dys and Nxf binding regions are
identical at 9/10 residues from residues 3 to 12 and are quite divergent from the Sim/Hif-1α/
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Trh and Ss/Ahr subgroups. The Caenorhabditis elegans C15C8.2 Dys/Nxf ortholog also shares
8/10 residues from residues 3–12. This Dys/Nxf sequence conservation likely contributes to
their binding to TC, unique among bHLH-PAS proteins and their similar affinities for AC and
GC. Some of these conserved amino acid residues are shared with other bHLH-PAS proteins.
The Sim/Hif-1α/Trh subgroup proteins all show identity to Dys/Nxf at Ala-7 and Arg-11 in
addition to Arg-12. This identity could contribute to the Dys/Nxf AC specificity. It has been
shown that both Ala-7 and Arg-11 amino acids are required for the binding of Hif-like factor-
Arnt to ACGTG (26). The Ss/Ahr basic regions share identity with Dys/Nxf at Ser-8 and Lys-9
in addition to Arg-12. This could contribute to the GC binding specificity of Dys/Nxf, and all
three residues are required for Ahr DNA binding (27). Thus, the Dys/Nxf basic region may
represent a hybrid protein structure that combines recognition elements both unique and similar
to those of other basic regions to bind a variety of DNA sequences.
Dys Regulation of Fusion Cell Transcription
The dys gene is expressed in all tracheal fusion cells and is required for proper branch fusion
in all branches except the dorsal trunk. Genetic analysis has shown that dys function is required
for transcription of four genes (CG13196, CG15252, mbo, and shg) and down-regulates levels
of Trh protein but not trh RNA (6,11). Other fusion-expressed genes are not regulated by
dys, although some of these, including dys, are regulated by the Escargot zinc finger protein
(28,29). The work described in this paper indicates that Dys/Tgo acts as a transcriptional
activator and directly regulates CG13196 expression. Thus, it is also possible that Dys/Tgo
directly regulates CG15252, mbo, and shg. Analysis of the sequence of these genes indicates
that all three have multiple TCGTG elements that could bind Dys/Tgo, although the expansive
intergenic sequences flanking CG15252 and shg make bioinformatic identification of relevant
fusion cell enhancers challenging. More promising for future analysis is the D. melanogaster
mbo gene, which has no introns and is closely wedged between Cyp313a4 and CG6188. It has
two TCGTG sequences and a single ACGTG in its 409-bp 3′-flanking region. Closely related
species of the D. melanogaster group have at least one of the TCGTG sequences present, often
accompanied by an ACGTG sequence, consistent with a role of TCGTG in Dys-mediated
transcription. However, the more distantly related Drosophila pseudoobscura and Drosophila
persimilis species have no TCGTG sequences in either the 5′ or 3′ intergenic regions. Future
transgenic and mutational work identifying mbo fusion cell enhancers in D. melanogaster and
the more distantly related D. pseudoobscura and D. persimilis species will be necessary to
understand how this gene is regulated by Dys.
In contrast, the negative regulation of trh is unlikely to be direct, since only Trh protein levels,
but not RNA levels, are reduced in dys mutants. Thus, Dys/Tgo is proposed to activate
transcription of a gene(s) that encodes a protein involved in translation or decay of Trh protein.
Consequently, Dys/Tgo may only be able to activate transcription, similar to Sim/Tgo (21).
Genetic evidence also suggests that Ss/Tgo, Sima/Tgo, and Trh/Tgo are generally, if not
exclusively, transcriptional activators (2,5). The dys target genes include two proteins involved
in cell adhesion (shg, CG13196), one that is in nuclear protein export (mbo) and another that
is possibly a cytoskeletal component (CG15252). In addition, dys may regulate expression of
a gene that controls Trh levels post-transcriptionally. This argues that Dys target genes
constitute a diverse family of genes, consistent with multiple roles in tracheal migration and
morphogenesis (11). It will be important to identify additional Dys/Tgo target genes and
determine whether they function in related cellular processes.
The results of dys misexpression data indicate that additional factors can influence Dys/Tgo
gene activation and also reveal a temporal aspect of fusion cell gene expression. Two aspects
of dys expression and function during embryogenesis stand out. One is that dys is expressed
in a relatively small, but diverse group of embryonic cell types (6). These include tracheal
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fusion cells, anal pad, foregut atrium, brain subset, and leading edge cells. Despite their
diversity, one feature of dys expression in these cell types is that its expression appears rather
late in embryogenesis, beginning at stage 12. Thus, dys activation of target gene expression,
although widespread spatially, is restricted temporally. When dys is expressed ectopically in
most tracheal cells, it can activate CG13196 expression in all of these cells at stage 15 or later
but not earlier at stages 11–14. Ectopic expression of dys in epidermal stripes and mesoderm
also results in widespread, but not uniform, expression at stages 15 and later but not earlier.
These temporal and spatial restrictions are unlikely to be due to restricted function of Tgo,
since tgo is ubiquitously expressed, and experiments with other bHLH-PAS proteins have
demonstrated that Tgo functions similarly in most, if not all, cell types throughout development
(5,16). Thus, there may be factors in tracheal cells that are absent or at lower levels in other
cell types that account for the enhanced ability of Dys/Tgo to activate transcription of
CG13196 in trachea and additional factors or chromatin states that allow Dys/Tgo to activate
transcription throughout the embryo at later stages of development but not earlier stages.
Another unusual result is the occurrence of GFP expression in only posterior fusion cells of P
[4X-TCGTG-GFP] embryos. GFP was not detected in anterior fusion cell units or other Dys-
positive embryonic cell types. Segmentally different Dys protein levels are unlikely to explain
the GFP differences. Levels of Dys protein are generally higher in fusion cells than in leading
edge, brain, and atrial foregut cells, but levels in the anal pad are comparable to fusion cells
(6). In addition, levels of Dys in anterior fusion cells are comparable to posterior fusion cells
as are levels of dys target gene expression (e.g. CG13196). Differences are also unlikely to be
due to the timing of detectable GFP accumulation, since anterior GFP expression was still
absent even in first instar larvae. Anterior repression is unlikely to be due to silencing by the
pH-Stinger vector, since the P[1.0-CG13196-GFP] pH-Stinger-based transgenes were
expressed in all fusion cells. Nor is it likely that the non-TCGTG sequences present in the 96-
bp 4×-TCGTG fragment mediates segmental differences, since the same fragment containing
ACGTG showed CNS midline and tracheal expression in all segments (2). Consequently,
anterior expression of Dys target genes may require a DNA binding factor in addition to Dys/
Tgo, whose binding site is absent from the P[4X-TCGTG-GFP] reporter transgene.
The Dys and Nxf proteins have unique basic region sequences. Not surprisingly, they also show
unique DNA binding specificities. Using identical assays, we showed that Sim/Tgo and Trh/
Tgo only bind ACGTG in transient transfection experiments (and also probably in vivo), but
Dys/Tgo and Nxf/Arnt strongly bind TCGTG, ACGTG, and GCGTG. One important question
concerns the functional significance of this binding site promiscuity. Our data currently leave
this issue unresolved. Because identical binding specificities are conserved between
Drosophila Dys/Tgo and mammalian Nxf/Arnt, this argues that the promiscuity is biologically
important. However, our in vivo mutational analysis of CG13196 provided evidence for a
requirement of TCGTG for fusion cell gene expression but not other NCGTG sequences.
However, these results demonstrated that ACGTG and GCGTG were not required by
themselves (i.e. sufficient); they did not rule out that either site might contribute to gene
activation with each other or with TCGTG sequences. The ACGTG and GCGTG sites could
also play a more prominent role in regulating other fusion cell target genes of Dys/Tgo or
controlling expression in other cell types.
Could the different binding sites for Dys/Tgo or Nxf/Arnt allow competitive or synergistic
interactions with other bHLH-PAS or bHLH proteins that use ACGTG or GCGTG binding
sites? This is an attractive possibility, but no evidence currently exists to support it. In
Drosophila, Dys is expressed in several non-tracheal embryonic sites, including the leading
edge, anal pad, foregut atrium, and brain cells. Yet, the presence in most of these cell types
does not obviously overlap with other bHLH-PAS proteins. The exception is the anal pad, in
which sim is also expressed (30). Dys and Trh are both expressed in tracheal fusion cells, but
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Dys levels increase during development, whereas Trh levels decrease. It is possible that Dys
could regulate expression of some Trh target genes, as Trh becomes increasingly unable to do
so, via the ACGTG sites in these genes. Another possibility is that Dys and Sima could
influence the tracheal transcriptional output of each other under conditions of hypoxia, since
Sima influences tracheal gene expression under hypoxic conditions (31,32). Similarly, Nxf and
Sim2 have been proposed to be co-expressed in subsets of mouse hippocampal cells (7).
However, in this case, it is proposed that Nxf levels are negatively regulated by direct repression
by Sim2, not that they act together. Although the conserved binding site specificities of Dys/
Tgo and Nxf/Arnt are intriguing, functional significance awaits direct in vivo tests and a greater
appreciation of the biological functions of these proteins.
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FIGURE 1. Dys binds Tgo, and transient transfection experiments with cultured Drosophila cells
indicate that Dys/Tgo binds multiple NCGTG sequences but prefers TCGTG
A, S2 cells were transfected with pAct-HA-dys (HA-Dys) and pAct-tgo (Tgo) individually or
in combination. Whole-cell extracts were prepared, and proteins were immunopurified with
anti-HA beads. Both cell extracts (Input) and HA pulldown complexes were subjected to 10%
SDS/PAGE followed by Western blot analysis with anti-Tgo mAb. Low levels of endogenous
Tgo were present in S2 cells without introduction of pAct-tgo, but the addition of pAct-Tgo
greatly increased Tgo levels. Anti-Tgo recognized a protein bound to HA-Dys when cells were
transfected with both pAct-HA-dys and pAct-tgo but not when either was absent. The position
of the 75-kDa marker protein is shown at the left. The protein reacting with anti-Tgo was 72
kDa, identical to the predicted size of Tgo. B–E, all transfections were independently performed
6×, and the results were averaged and normalized for pAc5.1/V5-His/lacZ expression. B, S2
cells were transfected with combinations of expression plasmids (pAct-dys, pAct-dys-Δb, pAct-
tgo) and reporter plasmids (4xACGTG-luc, 4xCCGTG-luc, 4xGCGTG-luc, 4xTCGTG-luc,
pGL3 (−; luc negative control)). C, S2 cells were transfected with combinations of expression
plasmids: pAct-sim, pAct-tgo, and the same reporters used in A. D, S2 cells were transfected
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with combinations of expression plasmids: pAct-trh, pAct-tgo, and the same reporters used in
B. E, S2 cells were transfected with combinations of expression plasmids pAct-Nxf, pAct-Arnt,
pAct-tgo, and the same reporters used in B. Vertical lines at the top of each column indicate
standard deviation.
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FIGURE 2. Dys dimerizes with Tgo in vivo
All embryos were stained with anti-Dys (magenta; A, D, G, J, M, and P) and anti-Tgo (green;
B, E, H, K, N, and Q). Merge images are shown in C, F, I, L, O, and R. dys mutant embryos
are dys2/dys3. Proteins derived from both alleles are predicted to lack the region that reacts
with anti-Dys. Thus, mutant embryos can be identified based on the absence of Dys
immunoreactivity. A–C, sagittal view of a wild-type stage 14 embryo showing overlap of Dys
and Tgo in nuclei of leading edge cells (arrowheads). D–F, sagittal view of a stage 14 dys
mutant embryo showing the absence of nuclear Tgo in the leading edge cells (arrowheads).
G–I, sagittal view of a stage 14 wild-type embryo showing the presence of nuclear Tgo in Dys-
positive tracheal fusion cells. Dorsal branch fusion cell (arrows) and dorsal trunk fusion cells
Jiang and Crews Page 16













(arrowheads) are shown. Note that the levels of nuclear Tgo were higher in fusion cells than
adjacent tracheal cells. J–L, sagittal view of a stage 14 dys mutant embryo showing that dorsal
trunk fusion cells (arrowheads) had reduced nuclear Tgo with levels comparable to adjacent
tracheal cells. M–O, ventral view of a stage 11 en-Gal4 UAS-dys embryo showing the ectopic
nuclear colocalization of Tgo and Dys in en stripes. P–R, ventral view of a stage 11 en-Gal4
UAS-dys-Δb embryo showing ectopic nuclear colocalization of Tgo and Dys-Δb.
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FIGURE 3. 1.0-kb fragment of the CG13196 gene directs fusion cell expression
A, schematic of 985 bp of D. melanogaster DNA 5′ to exon 1 of the CG13196 gene. The location
of exon 2 of the Buffy gene is shown. Arrows indicate the direction of transcription, and scale
is shown below the schematic. Five NCGTG sequences are located in this region: 3 TCGTG,
1ACGTG, and 1 GCGTG. B–D, dorsal-lateral view of a stage 16 embryo containing a P[1.0-
CG13196-GFP] transgene, in which the 1.0-kb CG13196 fragment cloned into the pH-
Stinger vector drives GFP expression. The embryo was hybridized to GFP (green) (B) and
CG13196 (magenta) (C) probes. Merge is in D. The two probes showed complete overlap in
expression in all fusion cells, including dorsal branch (arrows), dorsal trunk (white
arrowheads), and lateral trunk (yellow arrowhead).
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FIGURE 4. Fusion cell expression of CG13196 requires TCGTG sequences
All images show sagittal views of dorsal trunk fusion cells from transgenic stage 15 embryos
stained with anti-GFP (green) and anti-Dys (magenta); anterior is to the left. Dys staining acts
as a marker for the presence of fusion cells. A and B, P[1.0-CG13196-GFP] strain, which has
unmutated NCGTG sequences, showed GFP expression in fusion cells. C and D, P[1.0-mut
(all)-CG13196-GFP] strain, in which all 5 NCGTG sites were mutated, lacked fusion cell
GFP expression. E and F, P[1.0-mut(3TCGTG)-CG13196-GFP], in which all TCGTG sites
were mutated, lacked fusion cell GFP expression. G and H, P[1.0-mut(ACGTG)-CG13196-
GFP], in which the single ACGTG was mutated, showed fusion cell GFP expression. I and
J, P[1.0-mut(GCGTG)-CG13196-GFP], in which the single GCGTG was mutated, showed
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fusion cell GFP expression. K and L, the P[4X-TCGTG-GFP] strain showed GFP expression
in fusion cells. M, the P[4X-TCGTG-GFP] strain showed segmental differences in fusion cell
GFP expression. In this embryo GFP (green) was expressed in dorsal trunk fusion cells (yellow
arrowheads) in dorsal trunk units 3–9 but was absent in units 1–2 (see Manning and Krasnow
(33) for a description of tracheal metameric units) even though Dys protein (magenta) was
present (shown are units 2–9). Lateral trunk fusion cells (white arrowheads) showed the
appearance of GFP in units 5–9, but GFP was absent in units 1–4 even though they possessed
high levels of Dys (shown are units 2–9). N and O, expression of P[4X-TCGTG-GFP] was
absent in dys mutant embryos. The dys mutant embryo lacked (N) GFP (green) expression in
fusion cells, which were marked by staining with an antibody to the fusion cell-expressed Dead
end (Dnd) protein (magenta; Jiang and Crews, unpublished information).
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FIGURE 5. Misexpression of dys results in ectopic expression of Dys target gene CG13196 in
multiple cell types
Shown are sagittal views of embryos hybridized to a CG13196 RNA probe (magenta) and
immunostained with anti-Dys (green). Merge image is shown at the right. All embryos
contained the UAS-dys transgene and various Gal4 drivers. A–C, stage 16 btl-Gal4 UAS-dys
embryo showed ectopic CG13196 expression in all tracheal cells. D–F, stage 14 btl-Gal4 UAS-
dys embryo did not express CG13196 despite strong Dys misexpression in tracheal cells. G–
I, stage 16 en-Gal4 UAS-dys embryo showed CG13196 expression in en epidermal stripes.
Expression was observed in a subset of En-positive cells in the dorsal-lateral epidermis
(arrows) and was absent from the ventral epidermis (arrowheads). J–L, stage 12 en-Gal4 UAS-
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dys embryo did not express CG13196 in epidermal stripes even though strong en expression
was present. M–O, CG13196 was ectopically expressed in mesodermal cells in stage 16 twi-
Gal4 UAS-dys embryos. Not all Dys-positive cells expressed CG13196. P–R, stage 16 sca-
Gal4 UAS-dys embryo showed widespread dys expression in nerve cells (Q), yet CG13196
was only expressed in a small number of sca-positive cells (examples are indicated by yellow
arrowheads). Many CG13196-positive cells shown are tracheal fusion cells. Shown are dorsal
trunk (arrow) and longitudinal trunk (white arrowheads) fusion cells.
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TABLE 1
Basic region alignment of selected bHLH-PAS proteins
Basic region sequences are shown along with binding site specificity for each protein. · indicates amino acid identity,
and basic region numbering is at the top. Species prefixes arc: C. elegans (C), Drosophila (D), human (H), and mouse
(M). Proteins are Dysfusion (Dys), Nxf, C15C8.2, Single-minded (Sim), Single-minded-1 (Sim1), Similar (Sima),
Hypoxia-inducible Factor-1α (Hif-1α). HIF-like factor (Hlf). Trachealess (Trh). Spineless (Ss), and Aryl hydrocarbon
receptor (Ahr).
Protein Basic region Binding site
1 6 12
D-Dys NKSTKGASKMRR AC, GC, TC
H-Nxf YR · · · · · · ·A · · AC, GC, TC
C-C15C8.2 QR · · R · · · ·Q · · Unknown
D-Sim KEKS · N · ART · · AC
H-Sim1 KEKS · N · ART · · AC
D-Sima KEKSRD · ARC · · AC
H-Hif-1α KEKSRD · ARS · · AC
M-Hlf KEKSRD · ARC · · AC
D-Trh KEKSRD · ARS · · AC
D-Ss GVTKSNP · · RH · GC
H-Ahr EGIKSNP · · RH · GC
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